All In Biotech

Drug Trial Radar · NCT01209949

Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris

Last checked: Nov 20, 2026Latest source record: Aug 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

30

Actual

Start

Oct 2010

Primary completion

Jan 2011

Study completion Jan 2011

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Sep 27, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess subjects' experiences using Adapalene BPO gel to treat mild to moderate acne vulgaris using efficacy measurements, quality of life instruments, and video diaries.

Conditions

  • Acne Vulgaris

Interventions

  • Adapalene 0.1% and Benzoyl Peroxide 2.5% gelDrug

    Apply adapalene BPO gel once daily in the evening for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Were a Success (Subject's Global Assessment of 'Clear' or 'Almost Clear') at Week 12Time frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Thomas J. Stephens and Associates

    Carrollton, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.